2014-11-13T10:35:37-06:00 2014-06-30 410746749 CLIFTONLARSONALLEN LLP 2301 VILLAGE DRIVE ST JOSEPH MO 64506 990 2013-07-01 431266906 PKD FOUNDATION PKDF 8169312600 8330 WARD PARKWAY NO 510 KANSAS CITY MO 641142000 RAY SMITH CHIEF FINANCIAL OFFICER 8169312600 2014-11-13 1 CARL L BIRDSELL CPA P00852768 8162328441 2013 2015-11-30 17:44:51Z JACKIE HANCOCK JR 8330 WARD PARKWAY NO 510 KANSAS CITY MO 641142000 9980974 0 X WWW.PKDCURE.ORG X 1982 MO PROMOTE PROGRAMS OF RESEARCH AND EDUCATION TO DISCOVER TREATMENTS AND A CURE FOR PKD. 17 17 49 2322 0 0 8994590 6811982 39300 0 -6808 3224 -21537 87692 9005545 6902898 877016 1769659 0 0 2790159 2813158 52327 22412 753486 2702304 2169319 6421806 6774548 2583739 128350 4726619 5023924 332038 500993 4394581 4522931 X PROMOTE PROGRAMS OF RESEARCH, ADVOCACY, EDUCATION, SUPPORT AND AWARENESS IN ORDER TO DISCOVER TREATMENTS AND A CURE FOR POLYCYSTIC KIDNEY DISEASE AND IMPROVE THE LIVES OF ALL IT AFFECTS. 0 0 2495401 1769659 RESEARCHSINCE ITS FOUNDING IN 1982, THE PKD FOUNDATION HAS INVESTED MORE THAN $33 MILLION IN RESEARCH, CLINICAL AND SCIENTIFIC GRANTS, AS WELL AS FELLOWSHIPS AND SCIENTIFIC MEETINGS, MAKING US THE SECOND LARGEST FUNDER OF POLYCYSTIC KIDNEY DISEASE (PKD) RESEARCH AFTER THE NATIONAL INSTITUTES OF HEALTH (NIH). THIS HAS LED TO NEW DISCOVERIES ABOUT PKD, INCLUDING IDENTIFYING THE GENES RESPONSIBLE FOR PKD, WHICH ENABLES RESEARCHERS TO INVESTIGATE POSSIBLE TREATMENTS. IN 2010, THE PKD FOUNDATION LAUNCHED THE ACCELERATING TREATMENTS TO PATIENTS (ATP) INITIATIVE, A COMPREHENSIVE, INTEGRATED RESEARCH AND DEVELOPMENT PROGRAM THAT REPRESENTS THE CORE OF OUR WORK. ATP AIMS TO SPEED UP DEVELOPMENT OF TREATMENTS WHICH COULD SLOW OR STOP THE PROGRESSION OF PKD. EACH OF THE PROGRAMS WITHIN ATP IS IMPORTANT AND INTERCONNECTED. THE FOUNDATION'S FISCAL YEAR INVESTMENTS IN ATP ARE OUTLINED BELOW.RESEARCH GRANTS: INVESTED $1,084,000 ON GRANT FUNDING TO 15 PKD RESEARCHERS WHO FOCUS ON THE DEVELOPMENT OF A TREATMENT FOR PKD OR ON UNDERSTANDING THE WAY IN WHICH CYSTS DEVELOP OR ENLARGE IN PKD.CORE GRANTS: INVESTED $227,000 TO SUPPORT CORE RESEARCH GRANTS SERVICES AND RESOURCES FOR PKD SCIENTISTS IN FOUR CORE LABS SO THAT FOUNDATION DOLLARS CAN BE LEVERAGED ACROSS THE PKD RESEARCH COMMUNITY.DRUG REPURPOSING: INVESTED $157,000 TO TEST DRUG CANDIDATES TO SEE IF THEY CAN TREAT PKD. TWO DRUG CANDIDATES WERE UNDER EVALUATION DURING THE FISCAL YEAR. PKD OUTCOMES CONSORTIUM PROJECT (PKDOC): INVESTED $295,000 IN WORKING WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR REGULATORY APPROVAL TO USE TOTAL KIDNEY VOLUME (TKV) AS AN INDICATOR FOR HUMAN CLINICAL TRIALS - A MORE APPROPRIATE MEASURE OF DISEASE PROGRESSION IN ADPKD. PKDOC SUBMITTED THE FINAL QUALIFICATION PACKAGE TO THE FDA AND EUROPEAN MEDICINES AGENCY (EMA) FOR APPROVAL OF TKV AS A PROGNOSTIC BIOMARKER IN MARCH 2014.SCIENTIFIC MEETINGS: INVESTED $50,000 TO FUND FOUR PKD-RELATED MEETINGS THAT BRING EXPERTS TOGETHER AND PROVIDE CONTINUING EDUCATION FOR HEALTH PROFESSIONALS. TISSUE DONATION PROGRAM: INVESTED $10,000 TO COORDINATE DONATIONS OF DISCARDED PKD KIDNEYS TO RESEARCH LABS, ALLOWING INDIVIDUALS TO ACTIVELY PARTICIPATE AND SUPPORT DISCOVERY RESEARCH. THE FOUNDATION CONTACTED RESEARCHERS ON BEHALF OF 15 PATIENTS HOPING TO DONATE THEIR DISCARDED TISSUE TO RESEARCH.CLINICAL TRIAL AWARENESS PROGRAM (CTAP): INVESTED $25,000 TO SUPPORT PARTICIPATION IN CLINICAL TRIALS BY RAISING AWARENESS THROUGH PKD FOUNDATION PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS. THREE ACT ALERTS WERE SENT IN FISCAL YEAR 2014. 1249416 EDUCATION AND SUPPORTTHE FOUNDATION PROVIDES LOCAL SERVICES THROUGH ITS MORE THAN 60 VOLUNTEER-RUN CHAPTERS ACROSS THE COUNTRY. THESE VOLUNTEERS BRING TO LIFE THE MISSION OF THE ORGANIZATION BY ENSURING THAT NO ONE FACES THIS DISEASE ALONE. EDUCATION MEETINGS PROVIDE VALUABLE INFORMATION FROM HEALTH CARE PROFESSIONALS, WHILE SUPPORT ACTIVITIES RANGE FROM LENDING A LISTENING EAR TO ORGANIZED GROUP OUTINGS. THIS YEAR ALONE, OUR CHAPTERS HELD 116 EDUCATION AND SUPPORT EVENTS.CHAPTERS RAISE FUNDS FOR THE FOUNDATION THROUGH EVENTS WHICH ALSO INCREASE AWARENESS OF PKD AND CONNECT LOCAL PATIENTS AND FAMILIES TO EACH OTHER. EIGHTY-FIVE CHAPTER FUNDRAISING AND THIRD PARTY EVENTS WERE HELD THIS YEAR. CHAPTERS ALSO RAISE AWARENESS AND MONEY THROUGH THE WALK FOR PKD, THE FOUNDATION'S SIGNATURE FUNDRAISING AND PUBLIC AWARENESS EVENT. THE WALK FOR PKD TAKES PLACE IN MORE THAN 50 CITIES ACROSS THE NATION EACH YEAR AND HAS RAISED NEARLY $22 MILLION SINCE 2000.ON A NATIONAL LEVEL, THE FOUNDATION PROVIDES IN-DEPTH RESOURCES AND EDUCATION ABOUT LIVING WITH PKD TO EMPOWER PEOPLE TO MANAGE THEIR HEALTH. OFFERINGS INCLUDE WEBINARS, VIDEOS, A MULTI-FACETED WEBSITE (PKDCURE.ORG/LEARN), ONLINE COMMUNITIES AND PRINT MATERIALS. THE BIENNIAL PKD NATIONAL CONVENTION IS THE FOUNDATION'S LARGEST EDUCATION EVENT. ADDITIONALLY, TEN WEBINARS WERE ATTENDED BY 1,438 PEOPLE. 1309147 AWARENESS AND ADVOCACYTHE FOUNDATION RAISES AWARENESS THROUGH MARKETING AND PUBLIC RELATIONS SO PEOPLE KNOW WHAT PKD IS, ABOUT THE FOUNDATION AND HOW TO DONATE. MARKETING MATERIALS INCLUDE PKD PROGRESS MAGAZINE, PKDNEWS MONTHLY EMAIL NEWSLETTER, SOCIAL MEDIA, DISCUSSION FORUMS, BLOGS AND PKDCURE.ORG. VOICES OF PKD (PKDCURE.ORG/VOICESOFPKD) FEATURES TESTIMONIALS AND STORIES ABOUT PEOPLE'S EXPERIENCES WITH THE DISEASE. THIS YEAR, 1,141 FREE INFORMATION PACKET REQUESTS WERE FULFILLED FOR THOSE JUST DIAGNOSED OR LOOKING TO LEARN MORE ABOUT PKD. THERE WAS A SIGNIFICANT INCREASE ON SOCIAL MEDIA, REACHING MORE THAN 17,000 FACEBOOK AND 3,600 TWITTER FOLLOWERS - AN INCREASE OF 5,620 PEOPLE FROM THE PREVIOUS YEAR. THE ELECTRONIC NEWSLETTER RECEIVED 65,516 OPENS, OUR WEBSITES RECEIVED 498,462 VISITS AND OUR BLOGS RECEIVED 78,904 VISITS. DISCUSSION FORUMS RECEIVED 1,917 VISITS AND TWO ISSUES OF PKD PROGRESS WERE SENT TO 27,694 MEMBERS OF THE PKD COMMUNITY.THE FOUNDATION PLAYS A KEY ROLE IN LEGISLATIVE ADVOCACY TO SUPPORT PKD-RELATED INITIATIVES. THE PKD ADVOCACY ACTION CENTER (PKDCURE.ORG/ADVOCATE) PROVIDES RESOURCES AND WAYS FOR PEOPLE TO ADVOCATE, AND THE FOUNDATION SENDS ADVOCACY ALERTS FOR LEGISLATIVE AND PUBLIC POLICY ISSUES IMPACTING PKD PATIENTS AND FAMILIES. THE FOUNDATION JOINS WITH OTHER KIDNEY DISEASE-RELATED ORGANIZATIONS IN EVENTS THAT ALLOW ADVOCATES TO MEET WITH MEMBERS OF CONGRESS TO RAISE AWARENESS OF PKD AND DISCUSS LEGISLATIVE PRIORITIES. PKD FOUNDATION STAFF MEMBERS AND PATIENTS ATTENDED TWO EVENTS IN WASHINGTON, D.C.: THE KIDNEY COMMUNITY ADVOCACY DAY HOSTED BY AMERICAN SOCIETY OF NEPHROLOGY AND THE KIDNEY PATIENT SUMMIT HOSTED BY THE NATIONAL KIDNEY FOUNDATION. TOGETHER, THE TWO ADVOCACY EVENTS INCLUDED 13 ORGANIZATIONS, 150 ADVOCATES AND 223 MEETINGS ON CAPITOL HILL. 5053964 1 1 0 1 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 1 1 0 1 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 20 0 49 1 0 0 0 0 0 1 1 0 0 0 0 X 17 17 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 0 AK AL AR CA CO CT FL GA HI IL KS KY MA MD ME MI MN MS NC ND NH NJ NM NV NY OH OK OR PA RI SC TN UT VA WA WI WV X X X RAY SMITH 8169312600 8330 WARD PARKWAY STE 510 KANSAS CITY MO 64114 X BENNETT ROBERT DIRECTOR 1.00 X 0 0 0 CONWAY PAUL DIRECTOR 1.00 X 0 0 0 GOODMAN SCOTT DIRECTOR 1.00 X 0 0 0 GUAY-WOODFORD DR LISA DIRECTOR 1.00 X 0 0 0 KLEBER KLEE DIRECTOR 1.00 X 0 0 0 NELSON BROCK DIRECTOR 1.00 X 0 0 0 NELSON RICHARD R DIRECTOR 1.00 X 0 0 0 ODLAND DWIGHT DIRECTOR 1.00 X 0 0 0 ROBERTS JULIA DIRECTOR 1.00 X 0 0 0 RONA JEFFREY DIRECTOR 1.00 X 0 0 0 RYAN ANNE DIRECTOR 1.00 X 0 0 0 WATNICK DR TERRY DIRECTOR 1.00 X 0 0 0 WOLFE HILARY DIRECTOR 1.00 X 0 0 0 CONDELLA FRANK CHAIRMAN 2.00 X X 0 0 0 COWLEY BEN MD VICE CHAIRMAN 2.00 X X 0 0 0 HAZELWOOD BLAISE TREASURER 1.00 X X 0 0 0 LIENHARD JEROME T II SECRETARY 1.00 X X 0 0 0 GODSEY GARY THRU 62013 PRESIDENT & CEO 40.00 X 187535 0 29356 HANCOCK JACKIE JR 122013 CEO 40.00 X 15417 0 2280 DAVIS-WINGATE MICHELLE CHIEF DEVELOPMNT OFFICER/INTERIM CEO 40.00 X 126153 0 34246 SMITH RAY CHIEF FINANCIAL OFFICER 40.00 X 122583 0 30034 ROME LORRIE INTERIM CHIEF SCIENTIFIC OFFICER 40.00 X 105338 0 27956 557026 0 123872 4 0 1 0 PRECLINOMICS PO BOX 68845 INDIANAPOLIS IN 46268 DRUG REPURPOSING EVALUATION 248423 1 6811982 339324 6811982 2444 2444 3037114 3036334 780 780 780 129057 41742 87315 87315 MISCELLANEOUS INCOME 900099 377 377 377 6902898 0 0 90916 1541971 1541971 3688 3688 224000 224000 462865 127758 206570 128537 1703336 1093664 364240 245432 108049 70140 19841 18068 365629 229300 75622 60707 173279 99268 44667 29344 16559 11412 5147 26000 26000 22412 22412 578750 533172 8827 36751 195024 195024 315741 156384 100130 59227 54715 30479 13723 10513 275483 157785 71044 46654 269527 181583 23381 64563 251076 246745 134 4197 17645 13033 2550 2062 8987 5147 2318 1522 EXTERNAL RESEARCH 119010 119010 DUES, FEES, MEMBERSHIPS 40802 14401 8051 18350 6774548 5053964 967098 753486 X 84511 35178 0 49333 191785 237537 3015079 3370212 1356882 1246284 56175 91249 54753 32107 215573 193216 28706 22357 23239 24178 4726619 5023924 309743 500993 22295 332038 500993 X 3274728 3403079 1119853 1119852 4394581 4522931 4726619 5023924 128350 0 X X 0 1 X 1 0 X 8359686 7528329 6838361 9195589 6811982 38733947 8359686 7528329 6838361 9195589 6811982 38733947 2826980 35906967 365 228 330 1638 2444 5005 41751 639 51 1237 129434 173112 38912064 321868 0.92280 0.92070 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS INCOME - 2009 AMOUNT: $ 41,751. 2010 AMOUNT: $ 639. 2011 AMOUNT: $ 51. 2012 AMOUNT: $ 1,237. 2013 AMOUNT: $ 377. FUNDRAISING INCOME - 2013 AMOUNT: $ 129,057. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 22507 22507 7256834 7279341 513967 128492 0 0 496555 483227 513967 1493749 2240624 28917 29376 22507 80800 124139 120807 128492 373438 560157 215573 193216 22357 22357 7407691 504793 504793 6902898 0 6902898 7279341 504793 504793 6774548 0 6774548 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION N/A 64000 NORTH AMERICA 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION N/A 160000 0 0 0 0 0 0 224000 0 224000 EUROPE (INCLUDING ICELAND & GREENLAND) CASH GRANT FOR RESEARCH 64000 ACH TRANSFER 0 NORTH AMERICA CASH GRANT FOR RESEARCH 80000 ACH TRANSFER 0 NORTH AMERICA CASH GRANT FOR RESEARCH 80000 ACH TRANSFER 0 3 0 0 0 0 0 0 0 PART I, LINE 2: ALL GRANTEES ARE REQUIRED TO SUBMIT AN ANNUAL RESEARCH PROGRESS REPORT AND AN ANNUAL INSTITUTIONAL FINANCIAL STATUS REPORT. MOST GRANTEES ARE ALSO REQUIRED TO SUBMIT INTERIM QUARTERLY PROGRESS REPROTS. PART I, LINE 3: EXPENDITURES ARE REPORTED AT THE AMOUNT OF THE GRANT AWARDED AND ARE ACCOUNTED FOR USING THE SAME METHOD IN THE ORGANIZATION'S FINANCIAL STATEMENTS. X X X X X X 1 GONSERGERBER LLP 9433 N KENTUCKY AVE KANSAS CITY MO 64157 DEVELOPMENT PLANNING AND PROSPECT MANAGEMENT 0 2122361 18308 2104053 MERRIGAN & CO 1012 EAST 55TH STREET KANSAS CITY MO 64110 DIRECT MAIL CONSULTING 0 486353 4104 482249 2608714 22412 2586302 AK AL AR CA CO CT FL GA HI IL KS KY MA MD ME MI MN MS NC ND NH NJ NM NV NY OH OK OR PA RI SC TN UT VA WA WI WV GRATITUDE BENEFIT 96657 96657 2905 23608 3683 PASTA PARTY 32400 32400 2890 4495 2000 2161 129057 129057 5795 28103 2000 5844 41742 87315 1 MAYO CLINIC COLLEGE OF MEDICINE 200 FIRST ST SW PLUMMER 5 ROCHESTER MN 55905 416011702 501(C)(3) 130767 CASH GRANT FOR RESEARCH - VARIOUS PROJECTS INCLUDING DATA EVALUATION RESEARCH PROJECT INDIANA UNIVERSITY SCHOOL OF MEDICINE 635 BARNHILL DR INDIANAPOLIS IN 46202 356001673 501(C)(3) 31832 CASH GRANT FOR RESEARCH CRITICAL PATH INSTITUTE 1730 E RIVER ROAD SUITE 200 TUCSON AZ 85718 201991334 501(C)(3) 208347 CASH PAYMENTS FOR DATA EVALUATION RESEARCH PROJECT EMORY UNIVERSITY 1599 CLIFTON ROAD NE ATLANTA GA 30322 580566256 501(C)(3) 8513 CASH PAYMENTS FOR DATA EVALUATION RESEARCH PROJECT UNIVERSITY OF COLORADO DEPARTMENT 238 DENVER CO 809210238 846000555 501(C)(3) 12637 CASH PAYMENTS FOR DATA EVALUATION RESEARCH PROJECT KANSAS UNIVERSITY ENDOWMENT ASSOCIATION 3901 RAINBOW BLVD KANSAS CITY KS 66160 480547734 501(C)(3) 285000 CASH GRANTS FOR RESEARCH BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVE BOSTON MA 02115 042774441 501(C)(3) 80000 CASH GRANT FOR RESEARCH FASEB SUMMER RESEARCH CONFERENCE 9650 ROCKVILLE PIKE BETHESDA MD 20814 520700497 501(C)(3) 50000 GRANTS FOR SCIENTIFIC MEETINGS FOX CHASE CANCER CENTER 333 COTTMAN AVE PHILADELPHIA PA 19111 232003072 501(C)(3) 80000 CASH GRANT FOR RESEARCH INTERNATIONAL PEDIATRIC NEPHROLOGY ASSOCIATION 10833 LE CONTE AVE LOS ANGELES CA 90095 133352209 501(C)(3) 5000 2013 INTERNATIONAL PEDIATRIC NEPHROLOGY ASSOCIATION MEETING TUFTS MEDICAL CENTER PHYSICIANS ORGANIZATION INC 750 WASHINGTON ST BOSTON MA 02111 042743894 501(C)(3) 51754 CASH PAYMENTS FOR DATA EVALUATION RESEARCH PROJECT UNIVERSITY OF ALABAMA AT BIRMINGHAM 14720 2ND AVE S BIRMINGHAM AL 35294 636005396 501(C)(3) 80000 CASH GRANT FOR RESEARCH UNIVERSITY OF MARYLAND MEDICAL CENTER PO BOX 41428 BALTIMORE MD 21203 526002033 501(C)(3) 80000 CASH GRANT FOR RESEARCH UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 756002868 501(C)(3) 80000 CASH GRANT FOR RESEARCH YALE UNIVERSITY PO BOX 1872 NEW HAVEN CT 06508 060646973 501(C)(3) 320339 CASH GRANTS FOR VARIOUS RESEARCH PROJECTS UNIVERSITY OF MARYLAND FACULTY PHYSICIANS 419 W REDWOOD ST STE 660 BALTIMORE MD 21201 521299563 501(C)(3) 37781 CASH GRANT FOR RESEARCH 16 0 PART I, LINE 2: ALL GRANTEES ARE REQUIRED TO SUBMIT AN ANNUAL RESEARCH PROGRESS REPORT AND AN ANNUAL INSTITUTIONAL FINANCIAL STATUS REPORT. MOST GRANTEES ARE ALSO REQUIRED TO SUBMIT INTERIM QUARTERLY PROGRESS REPORTS. X X 0 0 0 0 0 0 0 0 0 GODSEY GARY THRU 62013 PRESIDENT & CEO 187535 0 0 0 0 0 11815 0 17541 0 216891 0 0 0 DAVIS-WINGATE MICHELLE CHIEF DEVELOPMNT OFFICER/INTERIM CEO 126153 0 0 0 0 0 9461 0 24785 0 160399 0 0 0 SMITH RAY CHIEF FINANCIAL OFFICER 122583 0 0 0 0 0 9194 0 20840 0 152617 0 0 0 X 21 107970 FAIR VALUE X RAFFLE ITEMS 246 82056 FAIR VALUE X ADVERTISING 12 52930 FAIR VALUE X TRAVEL 34 50880 FAIR VALUE X FOOD & BEVERA 71 28888 FAIR VALUE X EVENT ITEMS 32 16600 FAIR VALUE 0 0 1 1 PART I, COLUMN (B): TOTAL NUMBER OF DONORS PART I, LINE 32B: ORGANIZATION UTILIZES ONGOING BANKING RELATIONSHIPS TO MARKET DONATED SECURITIES. 990 PAGE 4, PART IV, LINE 11F: THE ORGANIZATION CONSIDERED UNCERTAIN TAX POSITIONS UNDER FIN 48 (ASC 740) AND DETERMINED THAT NO LIABILITY FOR UNCERTAIN TAX POSITIONS SHOULD BE RECORDED AS OF JUNE 30, 2014. THEREFORE, THERE IS NO FOOTNOTE REGARDING SUCH LIABILITY IN THE ORGANIZATION'S FINANCIAL STATEMENTS. FORM 990, PART VI, SECTION B, LINE 11 THE FORM 990 IS PREPARED BY AN INDEPENDENT ACCOUNTING FIRM. PRIOR TO FILING THE 990 FOR PKD FOUNDATION, A DRAFT COPY WILL BE PROVIDED TO THE BOARD OF TRUSTEES FOR REVIEW AND COMMENT. ANY COMMENTS WILL BE ACCUMULATED BY MANAGEMENT AND ADDRESSED ACCORDINGLY. FORM 990, PART VI, SECTION B, LINE 12C MEMBERS OF THE BOARD OF TRUSTEES OF PKD FOUNDATION ARE REQUIRED TO SIGN AN ANNUAL STATEMENT DISCLOSING ANY CONFLICTS OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 ANNUALLY, THE CHAIRMAN OF THE BOARD OF TRUSTEES WORKS WITH THE CEO TO DEVELOP THE CEO'S GOALS FOR THE NEW FISCAL YEAR. AT THE END OF EACH FISCAL YEAR, THE EXECUTIVE COMMITTEE EVALUATES THE CEO AGAINST THESE GOALS AND RECOMMENDS TO THE BOARD THE CEO'S COMPENSATION PACKAGE, FOR APPROVAL, BASED ON THIS EVALUATION. ANNUALLY, THE EXECUTIVE COMMITTEE REVIEWS A NATIONAL SALARY SURVEY CONDUCTED BY AN INDEPENDENT CONSULTANT. UPON THAT REVIEW, SALARIES ARE COMPARED TO THE RANGES RECOMMENDED FOR EACH POSITION. FOUNDATION MANAGEMENT THEN ACTS TO ENSURE THAT SALARIES ARE WITHIN APPROPRIATE RANGES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON THEIR OWN WEBSITE AND UPON REQUEST. FORM 990, PART VII, SEC. A: PKD FOUNDATION CONTRACTS WITH INSPERITY TO PROVIDE CERTAIN EMPLOYEE BENEFITS AND PAYROLL SERVICES. EMPLOYEES ARE CONSIDERED TO BE JOINTLY EMPLOYED BY BOTH PKD FOUNDATION AND INSPERITY. IN ORDER TO COMPLY WITH TRANSPARENCY DIRECTIVES AS A PART OF THE REFORMATTED 990, THE FOUNDATION HAS DECIDED TO REPORT COMPENSATION IN PART VII TO INCLUDE AMOUNTS PAID AND REPORTED ON W-2'S BY INSPERITY. FORM 990, PART XII, LINE 2C: THE ORGANIZATION HAS A COMMITTEE THAT ASSUMES RESPONSIBILITY FOR THE AUDIT AND SELECTION OF AN INDEPENDENT ACCOUNTANT. THERE HAS BEEN NO CHANGE IN THIS PROCESS FROM THE PRIOR YEAR.